UCP2 and leukemia: Two evidences suggest that UCP2 targeting might be a potential therapeutic strategy for HCC, (a) UCP2 overexpressing colon cancer cells are more resistant to CPT-11, ((4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl [1,4′-bipiperidine]-1′-carboxylic acid ester hydrochloride), a topoisomerase I inhibitor and (b) genipin, a specific UCP2 inhibitor, enhanced sensitization to anthracyclin to drug-resistant leukaemia cells [16,17].